drugset / Trial / NCT00005010

Prevention of Kidney Transplant Rejection

NCT00005010

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to see how effective 2 drugs, irbesartan and pravastatin, are at slowing kidney transplant failure. Many kidney transplant patients have some type of chronic rejection. Chronic rejection is a disease that causes scarring and damage to the kidney. Over time, chronic rejection can lead to kidney failure, making it necessary for patients to start dialysis and possibly receive another kidney transplant. Doctors would like to see whether irbesartan and pravastatin can slow this damage and prevent kidney failure in patients with signs of chronic rejection.

Timeline

Start
Primary completion
Completion
2004-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Irbesartan Small molecule 300 mg
Subject Pravastatin Small molecule 20 mg